JP2015530359A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530359A5
JP2015530359A5 JP2015521668A JP2015521668A JP2015530359A5 JP 2015530359 A5 JP2015530359 A5 JP 2015530359A5 JP 2015521668 A JP2015521668 A JP 2015521668A JP 2015521668 A JP2015521668 A JP 2015521668A JP 2015530359 A5 JP2015530359 A5 JP 2015530359A5
Authority
JP
Japan
Prior art keywords
antibody
seq
item
tumors
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015521668A
Other languages
English (en)
Japanese (ja)
Other versions
JP6336696B2 (ja
JP2015530359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049368 external-priority patent/WO2014011489A2/en
Publication of JP2015530359A publication Critical patent/JP2015530359A/ja
Publication of JP2015530359A5 publication Critical patent/JP2015530359A5/ja
Application granted granted Critical
Publication of JP6336696B2 publication Critical patent/JP6336696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015521668A 2012-07-10 2013-07-03 がんおよび自己免疫疾患の診断および治療に使用するためのモノクローナル抗体 Active JP6336696B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261669967P 2012-07-10 2012-07-10
US61/669,967 2012-07-10
US201261702916P 2012-09-19 2012-09-19
US61/702,916 2012-09-19
PCT/US2013/049368 WO2014011489A2 (en) 2012-07-10 2013-07-03 Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease

Publications (3)

Publication Number Publication Date
JP2015530359A JP2015530359A (ja) 2015-10-15
JP2015530359A5 true JP2015530359A5 (https=) 2016-08-25
JP6336696B2 JP6336696B2 (ja) 2018-06-06

Family

ID=49916655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521668A Active JP6336696B2 (ja) 2012-07-10 2013-07-03 がんおよび自己免疫疾患の診断および治療に使用するためのモノクローナル抗体

Country Status (25)

Country Link
US (2) US9926380B2 (https=)
EP (2) EP3088421B1 (https=)
JP (1) JP6336696B2 (https=)
KR (1) KR102049222B1 (https=)
CN (1) CN104540522B (https=)
AU (1) AU2013288982B2 (https=)
CA (1) CA2883056C (https=)
CY (1) CY1121743T1 (https=)
DK (1) DK3088421T3 (https=)
EA (1) EA034033B1 (https=)
ES (1) ES2720291T3 (https=)
HR (1) HRP20190939T1 (https=)
HU (1) HUE043443T2 (https=)
IL (1) IL236664B (https=)
IN (1) IN2015DN00263A (https=)
LT (1) LT3088421T (https=)
MX (1) MX360984B (https=)
PH (1) PH12015500074B1 (https=)
PL (1) PL3088421T3 (https=)
PT (1) PT3088421T (https=)
RS (1) RS58755B1 (https=)
SI (1) SI3088421T1 (https=)
UA (1) UA114108C2 (https=)
WO (1) WO2014011489A2 (https=)
ZA (1) ZA201500247B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
SI3132247T1 (sl) * 2014-04-16 2021-12-31 Juno Therapeutics Gmbh Postopki, kompleti in naprava za povečanje populacije celic
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
EP3368092B9 (en) 2015-10-29 2020-07-29 Novartis AG Antibody conjugates comprising toll-like receptor agonist
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
CN111032076A (zh) 2017-06-14 2020-04-17 阿迪塞特生物公司 能够以hla限制性方式结合hla-a2/tyrd的抗体及其用途
CN108611322B (zh) * 2018-05-09 2020-02-11 邹畅 乳腺癌循环肿瘤细胞系ctc-3、培养基及ctc-3的建立方法和应用
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2021202798A1 (en) * 2020-04-02 2021-10-07 The United States Of America As Represented By The Secretary Of The Navy Antigen binding proteins to class 5 etec adhesins
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
US20240425583A1 (en) * 2021-07-26 2024-12-26 Michael H. Cardone Methods and compositions related to mcl-1 and bim heterodimer antibodies
WO2024102497A2 (en) * 2022-11-11 2024-05-16 Renovorx, Inc. Methods and apparatuses for delivering an agent through the vasa vasorum
WO2025049921A1 (en) * 2023-08-30 2025-03-06 University Of Louisville Research Foundation, Inc. Methods for single molecule resolution of near full-length immunoglobulin heavy and light chain repertoires

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4843092A (en) 1986-04-25 1989-06-27 Hitoshi Shichi Immunosuppressive agent
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
FR2658197B1 (fr) 1990-02-14 1992-05-22 Inst Nat Sante Rech Med Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE69936927T2 (de) 1998-10-21 2008-05-15 Altor Bioscience Corp., Miramar Polyspezifische bindemoleküle und deren verwendung
CA2487779C (en) 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
CA2452986C (en) 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003271175A1 (en) 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
EP1598368A4 (en) * 2003-01-20 2007-07-25 Chugai Pharmaceutical Co Ltd ANTI-PCI neutralizing ANTIBODY
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
US20070280951A1 (en) 2003-12-12 2007-12-06 Naoki Kimura Cell Death Inducing Agents
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
US20060045884A1 (en) 2004-08-26 2006-03-02 Board Of Regents Vaccines for autoimmune and infectious disease
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
PT1876236E (pt) * 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
US20090022687A1 (en) 2005-05-18 2009-01-22 Chugai Seiyaku Kabushiki Kaisha Novel Pharmaceuticals That Use Anti-HLA Antibodies
CA2662798A1 (en) 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
US20100150927A1 (en) 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
WO2009073163A1 (en) * 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
US20110293620A1 (en) * 2008-12-05 2011-12-01 Molldrem Jeffrey J Monoclonal Antibodies For Use In Diagnosis and Therapy of Cancers and Autoimmune Disease
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies

Similar Documents

Publication Publication Date Title
JP2015530359A5 (https=)
JP7849417B2 (ja) Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法
JP7838050B2 (ja) 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法
ES2968880T3 (es) Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo
ES2778651T3 (es) Receptores de antígeno quimérico y métodos de uso
AU2014225788B2 (en) Engager cells for immunotherapy
US20210252056A1 (en) Immune effector cells and molecular adaptors with an antigen cytokine complex for effective immunotherapy
JP2022501043A (ja) 抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法
JP2024178177A (ja) 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
JP7035170B2 (ja) 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
CN113286879A (zh) 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子
CN106632660A (zh) 识别ny‑eso‑1抗原短肽的tcr
JP2024054286A (ja) 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
JP2022513682A (ja) 抗ｃｄ３８免疫療法によりがんを処置するための組成物および方法
CN106478809A (zh) 识别prame抗原短肽的tcr
EP3957650A1 (en) Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
AU2013271428A1 (en) Human bispecific EGFRvIII antibody engaging molecules
CN114195894A (zh) 一种靶向4-1bb的抗体及其应用
US20220242960A1 (en) Ghr-106 chimeric antigen receptor construct and methods of making and using same
US9611321B2 (en) Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies
CN106478808B (zh) 识别ny-eso-1抗原短肽的t细胞受体
CN106336457B (zh) 识别mage‑a3抗原短肽的t细胞受体
CN106632658A (zh) 识别ny-eso-1抗原短肽的tcr
JP2022514815A (ja) ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞
CN106188274A (zh) 识别rhamm抗原短肽的t细胞受体